M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)
Sep. 17, 2021
M3814: oral DNA-PK selective kinase inhibitor
M3814
DNA-PK-selective kinase inhibitor oral efficacy in xenograft radiation models undisclosed screening and optimization Mol. Cancer Ther., Mar. 27, 2020 Merck KGaA, Darmstadt, DE
Loading...
